Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Delaware County Memorial Hospital
mi
from
Drexel Hill, PA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Delaware County Memorial Hospital
mi
from
Drexel Hill, PA
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
CCOP - MainLine Health
mi
from
Wynnewood, PA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
CCOP - MainLine Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Wellspan Health - York Cancer Center
mi
from
York, PA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Wellspan Health - York Cancer Center
mi
from
York, PA
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Dixie Regional Medical Center
mi
from
Saint George, UT
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Dixie Regional Medical Center
mi
from
Saint George, UT
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
LDS Hospital
mi
from
Salt Lake City, UT
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
St. Vincent Hospital
mi
from
Green Bay, WI
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
St. Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
St. Luke's Medical Center
mi
from
Milwaukee, WI
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
All Saints Cancer Center at All Saints Healthcare
mi
from
Racine, WI
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
All Saints Cancer Center at All Saints Healthcare
mi
from
Racine, WI
Click here to add this to my saved trials
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated:  11/13/2017
Saint John Regional Hospital
mi
from
Saint John,
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Status: Enrolling
Updated: 11/13/2017
Saint John Regional Hospital
mi
from
Saint John,
Click here to add this to my saved trials
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/16/2017
Oregon Health and Science University
mi
from
Portland, OR
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/16/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/16/2017
University of California Los Angeles Medical Center
mi
from
Los Angeles, CA
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/16/2017
University of California Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/16/2017
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/16/2017
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/16/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/16/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/16/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/16/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/16/2017
Virginia Oncology Associates
mi
from
Hampton, VA
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/16/2017
Virginia Oncology Associates
mi
from
Hampton, VA
Click here to add this to my saved trials
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/16/2017
Virginia Oncology Associates
mi
from
Norfolk, VA
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/16/2017
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/16/2017
Karmanos Cancer Institute
mi
from
Farmington Hills, MI
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/16/2017
Karmanos Cancer Institute
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
A Phase II Study of Sorafenib (Nexavar®) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer
Status: Enrolling
Updated:  11/20/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
A Phase II Study of Sorafenib (Nexavar®) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer
Status: Enrolling
Updated: 11/20/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Metformin for Rising PSA Remote Trial
M-RePoRT: Metformin - Rising PSA Remote Trial
Status: Enrolling
Updated:  11/27/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Metformin for Rising PSA Remote Trial
M-RePoRT: Metformin - Rising PSA Remote Trial
Status: Enrolling
Updated: 11/27/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
MBCCOP - JHS Hospital of Cook County
mi
from
Chicago, IL
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
MBCCOP - JHS Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Central Illinois
mi
from
Decatur, IL
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
MBCCOP - LSU Health Sciences Center
mi
from
New Orleans, LA
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
MBCCOP - LSU Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
mi
from
Shreveport, LA
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
mi
from
Shreveport, LA
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Beaumont
mi
from
Royal Oak, MI
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Beaumont
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Heartland Research Consortium
mi
from
Saint Louis, MO
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Heartland Research Consortium
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - St. Louis-Cape Girardeau
mi
from
Saint Louis, MO
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - St. Louis-Cape Girardeau
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
Alamance Cancer Center at Alamance Regional Medical Center
mi
from
Burlington, NC
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
Alamance Cancer Center at Alamance Regional Medical Center
mi
from
Burlington, NC
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
Southeastern Medical Oncology Center - Goldsboro
mi
from
Goldsboro, NC
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
Southeastern Medical Oncology Center - Goldsboro
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
Caldwell Memorial Hospital
mi
from
Lenoir, NC
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
Caldwell Memorial Hospital
mi
from
Lenoir, NC
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
Wake Forest University CCOP Research Base
mi
from
Winston-Salem, NC
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
Wake Forest University CCOP Research Base
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
Cancer Centers of the Carolinas - Easley
mi
from
Greenville, SC
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
Cancer Centers of the Carolinas - Easley
mi
from
Greenville, SC
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated:  11/27/2017
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Status: Enrolling
Updated: 11/27/2017
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Status: Enrolling
Updated:  11/29/2017
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Status: Enrolling
Updated: 11/29/2017
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials